Therefore, pharmacologically interrupting the JAK2/STAT3 signaling cascade emerges as a rational and promising strategy for developing anti‐HCC therapies that are capable of targeting both inflammation and tumor progression in an integrated manner. The gene discussed is STAT3; the disease is neoplasm.